An observational study in Heart Failure, Kidney Diseases and Kidney Injury, sponsored by Nanjing First Hospital, Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-02.
Sponsored by Nanjing First Hospital, Nanjing Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 45th largest by planned enrollment of the 130 observational ones that give a count, is one of 17 that started in 2016, is one of 130 observational ones, reaches primary completion later than 80 of the 181 other live ones, and was the 170th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 17 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
Nanjing First Hospital, Nanjing Medical University is the lead sponsor of 224 studies on the registry; 110 are open to participants now.
Nanjing First Hospital, Nanjing Medical University has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
Cardiorenal syndrome is a clinical syndrome caused by acute or chronic injury of one of the heart and kidney resulting to acute or chronic dysfunction of the other organ. In recent years, the morbidity of cardiorenal syndrome has increased rapidly in China. Its condition is complex and difficult to treat. Due to the lack of studies specifically targeting the cardiorenal syndrome population, there is no systematic in-depth understanding of the pathogenesis and risk factors of this kind of disease. In clinic, the course of various types of cardiorenal syndrome is complex and difficult to be summarized into a specific type. Therefore, we intend to conduct a clinical systematic observation and research on such patients so as to optimize a more reasonable treatment scheme.
Patients from a tertiary hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.
Exclusion Criteria:
Pregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.
Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
Other: guideline recommended routine treatment
Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease
Other: guideline recommended routine treatment
Hospitalization due to worsening of renal or cardiac function
eGFR continuously decreased by more than 25% within one year; NYHA cardiac function class III or above requires intravenous pharmacological agents; deterioration of cardiac or kidney function requiring dialysis
Time frame: 1 year
All-cause deaths
Deaths due to disease progression
Time frame: 1 year
End-stage renal disease requires maintenance dialysis
eGFR\<15ml/min, combined with one of the following conditions: 1. Uremia symptoms that cannot be alleviated by limiting protein intake; 2. Hyperkalemia that is difficult to correct; 3. Progressive metabolic acidosis that is difficult to control; 4. Uncontrollable water and sodium retention, combined with congestive heart failure or acute pulmonary edema; 5. Uremic pericarditis; 6. Uremic encephalopathy and progressive neuropathy.
Time frame: 1 year
Acute kidney injury
increase in Scr ≥0.3 mg/dL (26.5 μmol/L) within 48 h, or increase in Scr ≥1.5 times baseline in 7 days, or urine volume \<0.5 mL/kg/h for 6 h.
Time frame: 1 year
Started Jan 2016 (actual). Primary completion is estimated for Dec 2026, 131 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 131 months is above that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing First Hospital, Nanjing Medical University →